Biocept Inc. (BIOC) stock declines during pre-market trading. Here’s what’s happening?

0
477
AI Stocks
AI Stocks

Biocept Inc. (NASDAQ: BIOC) stock gained by 4.24% at last close whereas the BIOC stock-price plunge by 7.59% in the pre-market trading session. Biocept creates and sells molecular diagnostic tests that offer clinicians with clinically useful information to help in the diagnosis, therapy, and follow-up of cancer patients.

>> 7 Top Picks for the Post-Pandemic Economy << 

BIOC stock’ Current Development

New research from Biocept shows that the company’s CNSide cerebrospinal fluid assay discovered tumor cells and detected actionable mutations in lung cancer patients with leptomeningeal carcinomatosis, enabling for tailored therapy options that might improve outcomes and lengthen life expectancy. The findings were to be presented as a poster at the Society for Neuro-(SNO) Oncology’s Third Annual Conference on Brain Metastases, held virtually on Aug. 19-20, 2021.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Read More

Clinical assessment, imaging, and cytology are the most common methods for diagnosing LMC, however they have poor sensitivity. The typical patient’s life expectancy is only four to six weeks if they are not treated.

The University of Utah Huntsman Cancer Institute employed Biocept’s CNSide test to identify and characterize tumor cells in the cerebrospinal fluid of 15 different individuals in a retrospective analysis. CNSide identified tumor cells in 100 percent of the samples examined with LMC, whereas cytology discovered tumor cells in just 40% of the samples. CNSide also discovered actionable indicators in tumor cells, allowing doctors to make tailored therapy decisions that decreased severe symptoms and, in some cases, increased patient survival by more than three years. The findings show that CNSide is more accurate than cytology, and that if an actionable target is found and medicated, patients with LMC can live longer.

>> 7 Top Picks for the Post-Pandemic Economy << 

Michael C. Dugan, BIOC Stock Chief Medical Officer and Medical Director stated,

It’s important to find actionable mutations while treating LMC patients. CNSide has shown that it can consistently identify and evaluate tumor cells in cerebrospinal fluid that aren’t present in blood or tissue samples. The precise molecular targets found in these tumor cells can lead a physician’s choice of newer, more effective treatments and impact the effectiveness of therapy in a way that can enable these patients achieve dramatic improvements in their symptoms and live much longer lives.

LEAVE A REPLY

Please enter your comment!
Please enter your name here